Lung Function Reduced in LOPD Despite Long-term Myozyme Use

Lung Function Reduced in LOPD Despite Long-term Myozyme Use

313145

Lung Function Reduced in LOPD Despite Long-term Myozyme Use

Despite treatment for years with Myozyme (alglucosidase alfa) — marketed in the U.S. as Lumizyme — people with late-onset Pompe disease (LOPD) still develop airway abnormalities and experience reduced lung function, a small Taiwanese retrospective study shows. While none of the five patients in the study required a ventilator or feeding tube, all developed respiratory complications to include sleep disorder breathing. According to the researchers, regular monitoring of pulmonary function, including visualization of the deep airways…

You must be logged in to read/download the full post.